Who's Making Headlines?
This drug has recently re-entered the MM market with a community-friendly, non-hospitalization narrative
What is belantamab mafodotin
Compared with teclistamab, elranatamab is anticipated to be available as this (at least in the near-term future)
What is a monotherapy
The majority of patients at first relapse are expected to be treated in this setting
What is the community
This phase 3 trial is evaluating elranatamab as maintenance therapy posttransplant
What is MagnetisMM-7
This drug is anticipated to be the first CELMoD to enter the 2L+ MM market
What is iberdomide (in combination with Dd)
Regimens that include this therapy class as backbone is generally preferred in 2L for patients who have not yet been exposed
What is anti-CD38 mAb
Most patients at first relapse are expected to be exposed to this therapy class in 1L
What is anti-CD38 mAb
MagnetisMM-6 pits elranatamab against this regimen
What is DVRd
Many HCPs consider this therapy top-of-mind for younger, fitter patients
What is CAR T-cell therapy
The route of administration for CELMoDs is this
What is oral
With multiple drugs and MOAs anticipated to become available in 2L+ MM, this is a top concern among HCPs
What is lack of treatment sequencing guidance
These treatment interventions in ElLen and CARTITUDE-6 are going up against transplant in NDMM
What is elranatamab + lenalidomide and cilta-cel, respectively